A taxonomy of pragmatic measures of HIV preexposure prophylaxis use.

OBJECTIVES As delivery of preexposure prophylaxis (PrEP) becomes an HIV prevention priority in the United States, standard, pragmatic measures of PrEP use are needed to compare and evaluate prevention implementation programs. By using readily available electronic health record data, we describe and compare measures of persistence and retention. DESIGN Retrospective cohort. METHODS Using electronic health record prescription data for patients at a large urban Federally Qualified Health Center from 2015 to 2019, we calculated measures of persistence and retention and compared them to pharmacy claims data, PrEP biomarkers, and HIV outcomes. RESULTS Total PrEP time was 19.8 months on average. During this period, average adherence by medication prescription ratio (MRxR) was 89%; 77% of patients had an MRxR at least 85% and 90% have an MRxR at least 57%. Over the first 6 months, average proportion of days covered (PDC) at least 85% was 53% and PDC at least 57% was 57%. Prescription fill rates, based on claims data from a pharmacy partner, ranged from 45 to 60%. Using tenofovir-diphosphate as the gold standard, PDC had high sensitivity (97%) but low specificity (≤13%). As a measure of retention, over the first 6 months, 59% of patients had quarterly HIV tests. CONCLUSION Total PrEP time is useful measure of overall persistence, while PDC can assess persistence and adherence at a specific time point. Adherence by PDC is more conservative compared with MRxR; both will overestimate true adherence. Retention in care can be measured by quarterly HIV tests. Using consistent terminology and reporting timepoints and adherence thresholds will help reporting and comparing PrEP delivery programs.

[1]  C. Delaugerre,et al.  On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial. , 2019, The lancet. HIV.

[2]  Christel Hyden,et al.  Predictors of Disengagement in Care for Individuals Receiving Pre-exposure Prophylaxis (PrEP). , 2019, Journal of acquired immune deficiency syndromes.

[3]  K. Mayer,et al.  Patterns and clinical consequences of discontinuing HIV preexposure prophylaxis during primary care , 2019, Journal of the International AIDS Society.

[4]  Michael R. Kramer,et al.  The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. , 2018, Annals of epidemiology.

[5]  Matthew A Hevey,et al.  PrEP Continuation, HIV and STI Testing Rates, and Delivery of Preventive Care in a Clinic-Based Cohort. , 2018, AIDS education and prevention : official publication of the International Society for AIDS Education.

[6]  M. Golden,et al.  Patient Disengagement From an HIV Preexposure Prophylaxis Program in a Sexually Transmitted Disease Clinic , 2018, Sexually transmitted diseases.

[7]  Arthi Ramachandran,et al.  Preexposure Prophylaxis Initiation and Retention in Care Over 5 Years, 2012–2017: Are Quarterly Visits Too Much? , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  R. Gandhi.  Preexposure Prophylaxis for the Prevention of HIV , 2018 .

[9]  E. Vittinghoff,et al.  Provider Adherence to Pre-exposure Prophylaxis Monitoring Guidelines in a Large Primary Care Network , 2018, Open forum infectious diseases.

[10]  K. Look,et al.  Refill-Based Medication Use Quality Measures in Kidney Transplant Recipients: Examination of Proportion of Days Covered and Medication Possession Ratio , 2018, Journal of managed care & specialty pharmacy.

[11]  M. Vaughan-Sarrazin,et al.  Medication Adherence in a Nationwide Cohort of Veterans Initiating Pre-exposure Prophylaxis (PrEP) to Prevent HIV Infection , 2017, Journal of acquired immune deficiency syndromes.

[12]  S. Buchbinder,et al.  Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy , 2017, Antimicrobial Agents and Chemotherapy.

[13]  C. B. Hare,et al.  Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation , 2016, Journal of acquired immune deficiency syndromes.

[14]  N. Webb,et al.  A Systematic Review of Insulin Adherence Measures in Patients with Diabetes , 2016, Journal of managed care & specialty pharmacy.

[15]  K. Mayer,et al.  Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical Setting , 2016, PloS one.

[16]  M. Mimiaga,et al.  Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities , 2016, Journal of the International AIDS Society.

[17]  J. Baeten,et al.  Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. , 2015, AIDS.

[18]  J. Steiner,et al.  Standardizing Terminology and Definitions of Medication Adherence and Persistence in Research Employing Electronic Databases , 2013, Medical care.

[19]  E. Gardner,et al.  Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. , 2012, AIDS research and human retroviruses.

[20]  Anuja Roy,et al.  Medication compliance and persistence: terminology and definitions. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.